10 Sales Behaviors That Prospects Hate
3 New Thoughts From the AXA US Individual Annuities Chief
Indexed Life Sales Rise 10%: Wink
John Doak, the Oklahoma insurance commissioner, today gave members of a Senate panel advice that would please many health insurance agents and brokers: He called for the Senate Committee on Health, Education, Labor and Pensions to investigate the Affordable Care Act Navigator program.
"I would ask for the full Senate committee to do an audit of the Navigator program," Doak told Sen. Tammy Baldwin, R-Wis., a Senate HELP Committee member. "Are they doing the job they're supposed to be doing? Where's the checks and balance there?"
Doak was one of five state insurance commissioners who appeared as witnesses at a Senate HELP hearing on stabilizing the individual major medical insurance market. The hearing is one of four the committee has scheduled on the topic for this week and the next. The other witnesses at today's hearing were Mike Kreidler of Washington state; Julie Mix McPeak of Tennessee; Teresa Miller of Pennsylvania; and Lori Wing-Heier of Alaska.
Top 10 Medical Stocks To Invest In 2019: Meridian Bioscience Inc.(VIVO)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Intellia Therapeutics (NASDAQ: NTLA) and Meridian Bioscience (NASDAQ:VIVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
- [By Logan Wallace]
VIVO (CURRENCY:VIVO) traded down 0.1% against the dollar during the 24 hour period ending at 0:00 AM Eastern on May 8th. In the last seven days, VIVO has traded down 9.4% against the dollar. One VIVO coin can now be bought for about $0.77 or 0.00008506 BTC on major cryptocurrency exchanges including Cryptopia, CryptoBridge and Stocks.Exchange. VIVO has a market cap of $1.41 million and approximately $9,560.00 worth of VIVO was traded on exchanges in the last day.
Top 10 Medical Stocks To Invest In 2019: Clean Energy Fuels Corp.(CLNE)
Advisors' Opinion:- [By Paul Ausick]
Clean Energy Fuels Corp. (NASDAQ: CLNE) dropped about 3.6% Wednesday to post a new 52-week low of $1.62 after closing at $1.68 on Tuesday. The stock’s 52-week high is $3.12. Volume was about 2 million, about 30% above the daily average of around 1.3 million. The company had no specific news.
- [By Jason Hall]
Natural gas for transportation supplier�Clean Energy Fuels Corp�(NASDAQ:CLNE) reported earnings on May 10, and while the company was profitable on both a GAAP and adjusted basis, growth -- measured in gallons of natural gas delivered -- slowed to almost a trickle, even when adjusted for last year's sale of the biomethane business. At the same time, the cyclical nature of its station construction and expansion business also affected the results, playing a role in a big decline in revenue.�
- [By Lisa Levin] Gainers Turtle Beach Corporation (NASDAQ: HEAR) surged 87.1 percent to $12.98 after the company reported Q1 results and raised its FY18 outlook. ARMO BioSciences, Inc. (NASDAQ: ARMO) shares jumped 66.8 percent to $49.735 after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. vTv Therapeutics Inc. (NASDAQ: VTVT) gained 34 percent to $2.2920 following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Prestige Brands Holdings, Inc. (NYSE: PBH) climbed 22.3 percent to $34.84 after the company posted upbeat Q4 earnings. Depomed, Inc. (NASDAQ: DEPO) shares jumped 22.2 percent to $7.28 following better-than-expected Q1 earnings. Everspin Technologies, Inc. (NASDAQ: MRAM) gained 19.8 percent to $8.89 after the company reported strong results for its first quarter. Luxfer Holdings PLC (NYSE: LXFR) surged 19.8 percent to $17.10 following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 18.3 percent to $2.26 after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Intelligent Systems Corporation (NYSE: INS) gained 17 percent to $7.116. Green Dot Corporation (NYSE: GDOT) surged 15.3 percent to $73.00 after reporting upbeat Q1 earnings. The Chefs' Warehouse, Inc. (NASDAQ: CHEF) climbed 15 percent to $28.85. Chefs' Warehouse posted Q1 earnings of $0.03 per share on sales of $318.6 million. Westport Fuel Systems Inc. (NASDAQ: WPRT) rose 14.2 percent to $2.9701. Wright Medical Group N.V. (NASDAQ: WMGI) jumped 13.8 percent to $23.87 after reporting upbeat quarterly earnings. Diplomat Pharmacy, Inc. (NYSE: DPLO) gained 13.4 percent to $22.70. Diplomat named Brian Griffin as Chairman and CEO. Carvana Co. (NYSE: CVNA) shares rose 13 percent to $27.97 after reporting upbeat Q1 sales. Prothena Corporation plc (NASDAQ: PRTA) gained 12 percent to $15.19
- [By Jason Hall]
Shares of�Clean Energy Fuels Corp.�(NASDAQ:CLNE) surged as much as 22.7% today, before losing a little steam in afternoon trading. As of 12:20 p.m. EDT, shares were up 13.6% in very heavy trading. At this writing, more than 5 million shares have traded hands, about five times the average volume for the company's stock.�
- [By Paul Ausick]
Clean Energy Fuels Corp. (NASDAQ: CLNE) saw a drop of about 6.3% in short interest to 4.2 million shares. About 3.1% of the company’s float was short, and days to cover rose from six to nine. The share price fell by 1.8% in the short interest period. The stock closed at $1.91 on Wednesday, up about 2.1% for the day, in a 52-week range of $1.31 to $3.05.
- [By Maxx Chatsko]
Depending on how investors look at the situation, natural gas transportation fuels leader Clean Energy Fuels (NASDAQ:CLNE) is either oh-so-close to finally cashing in on its long-term potential or on the doorstep of a much worse fate. Considering shares have fallen almost 80% in the last three years, it may seem difficult to remain optimistic. But there are some rays of sunshine piercing through the dark clouds.
Top 10 Medical Stocks To Invest In 2019: Helen of Troy Limited(HELE)
Advisors' Opinion:- [By Shane Hupp]
Helen of Troy (NASDAQ:HELE) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday.
- [By Ethan Ryder]
Deer Consumer Products (OTCMKTS: DEER) and Helen of Troy (NASDAQ:HELE) are both consumer discretionary companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Top 10 Medical Stocks To Invest In 2019: Magic Software Enterprises Ltd.(MGIC)
Advisors' Opinion:- [By Logan Wallace]
HC Wainwright set a $10.00 target price on Magic Software Enterprises (NASDAQ:MGIC) in a research note released on Thursday morning. The firm currently has a buy rating on the software maker’s stock.
- [By Lisa Levin]
Magic Software Enterprises Ltd. (NASDAQ: MGIC) is estimated to report quarterly earnings at $0.14 per share on revenue of $67.07 million.
Canadian Solar Inc. (NASDAQ: CSIQ) is projected to report quarterly earnings at $0.47 per share on revenue of $1.34 billion.
- [By Logan Wallace]
ValuEngine lowered shares of Magic Software Enterprises (NASDAQ:MGIC) from a buy rating to a hold rating in a report issued on Monday.
Several other equities research analysts have also recently issued reports on MGIC. Zacks Investment Research raised shares of Magic Software Enterprises from a sell rating to a hold rating in a research report on Wednesday, January 17th. BidaskClub cut shares of Magic Software Enterprises from a sell rating to a strong sell rating in a research report on Tuesday, January 23rd. Finally, HC Wainwright set a $10.00 target price on shares of Magic Software Enterprises and gave the stock a buy rating in a research report on Thursday, March 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $9.81.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Magic Software Enterprises (MGIC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 10 Medical Stocks To Invest In 2019: John B. Sanfilippo & Son, Inc.(JBSS)
Advisors' Opinion:- [By Max Byerly]
The Hershey (NYSE: HSY) and John B. Sanfilippo & Son (NASDAQ:JBSS) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.
Top 10 Medical Stocks To Invest In 2019: Laboratory Corporation of America Holdings(LH)
Advisors' Opinion:- [By Joseph Griffin]
Envestnet Asset Management Inc. reduced its position in shares of LabCorp (NYSE:LH) by 45.1% during the first quarter, HoldingsChannel.com reports. The fund owned 19,179 shares of the medical research company’s stock after selling 15,727 shares during the quarter. Envestnet Asset Management Inc.’s holdings in LabCorp were worth $3,116,000 at the end of the most recent reporting period.
- [By Max Byerly]
MUFG Americas Holdings Corp trimmed its stake in LabCorp (NYSE:LH) by 55.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,683 shares of the medical research company’s stock after selling 13,073 shares during the quarter. MUFG Americas Holdings Corp’s holdings in LabCorp were worth $1,728,000 as of its most recent filing with the Securities & Exchange Commission.
- [By Joseph Griffin]
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
Get Laboratory Corp. of America alerts: Stock Traders Buy Large Volume of Laboratory Corp. of America Put Options (LH) (americanbankingnews.com) Credit Suisse Group Lowers Laboratory Corp. of America (LH) to Hold (americanbankingnews.com) Laboratory Corp. of America (LH) Set to Announce Quarterly Earnings on Wednesday (americanbankingnews.com) Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings? (finance.yahoo.com) As Laboratory Corp Of America Holdings (LH) Shares Rose, Shareholder Veritas Investment Management Llp … (djzplanet.com)LH has been the subject of several research analyst reports. Craig Hallum restated a “buy” rating and set a $204.00 price target (up from $180.00) on shares of Laboratory Corp. of America in a research note on Wednesday, February 7th. Morgan Stanley upped their target price on Laboratory Corp. of America from $182.00 to $192.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. Zacks Investment Research downgraded Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Mizuho set a $178.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Robert W. Baird set a $183.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Thursday, February 8th. Seven investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $189.19.
Top 10 Medical Stocks To Invest In 2019: Sonic Corp.(SONC)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on Sonic Drive-In (SONC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Sonic Drive-In (NASDAQ:SONC) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
- [By Peter Graham]
Small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscal Q1 2018 earnings after the market closed Thursday that exceeded Wall Street expectations. Total revenues were $105.428 million versus $129.551 million as�system same-store sales declined 1.7% - consisting of a 1.6% same-store sales decrease at franchise drive-ins and a 3.2% decrease at company drive-in. Net income totaled $11.4 million versus net income of $13.1 million. The CEO commented:
Top 10 Medical Stocks To Invest In 2019: AmeriGas Partners, L.P.(APU)
Advisors' Opinion:- [By John Bromels]
If you're like me, you probably use branded propane tanks from�AmeriGas Partners�(NYSE:APU) or�Blue Rhino, which is owned by�Ferrellgas Partners, L.P.�(NYSE:FGP)�(Full disclosure: Propane is propane. I use AmeriGas because it's what the local convenience store sells.) Either one will get your burgers cooked, but which one will keep your portfolio cooking along?�
Top 10 Medical Stocks To Invest In 2019: PAREXEL International Corporation(PRXL)
Advisors' Opinion:- [By Logan Wallace]
News headlines about PAREXEL International (NASDAQ:PRXL) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PAREXEL International earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 49.4978250148766 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Top 10 Medical Stocks To Invest In 2019: Sarepta Therapeutics, Inc.(SRPT)
Advisors' Opinion:- [By Shane Hupp]
Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Sarepta Therapeutics (NASDAQ:SRPT) had its target price increased by Morgan Stanley from $87.00 to $91.00 in a report issued on Friday. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.
No comments:
Post a Comment